Spectrum Pharmaceuticals, Inc. (SPPI) Given a $11.00 Price Target at FBR & Co
The firm presently has a "buy" rating on the biotechnology company's stock. FBR & Co's price objective would indicate a potential upside of 72.68% from the company's previous close.
from Biotech News
0 Comments